Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Developmental therapeutics

535MO - BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma

Date

18 Sep 2020

Session

Mini Oral - Developmental therapeutics

Presenters

Juan Martin Liberal

Citation

Annals of Oncology (2020) 31 (suppl_4): S462-S504. 10.1016/annonc/annonc271

Authors

J. Martin Liberal1, P.C. Fong2, V. Moreno Garcia3, S. Frentzas4, J. Desai5, T. Meniawy6, B. Markman7, M. Voskoboynik6, N. Budha8, J. Wu9, W. Shen10, M. Singh11, E. Calvo12

Author affiliations

  • 1 Catalan Institute Of Oncology (ico), Hospitalet, 08908 - Barcelona/ES
  • 2 Medical Oncology, The University of Auckland and Auckland City Hospital, Auckland/NZ
  • 3 Start Madrid-fjd, Hospital Fundación Jiménez Díaz, 28040 - Madrid/ES
  • 4 Monash Health, Monash University, Clayton/AU
  • 5 Peter Maccallum Cancer Centre, Royal Melbourne Hospital, 3000 - Melbourne/AU
  • 6 Medical Oncology, Linear Clinical Research, Nedlands/AU
  • 7 Monash University, Alfred Hospital, Melbourne/AU
  • 8 Clinical Pharmacology, BeiGene USA, Inc., San Mateo/US
  • 9 Biostatistics, BeiGene USA, Inc., San Mateo/US
  • 10 Clinical Development, BeiGene (Beijing) Co., Ltd., Beijing/CN
  • 11 Clinical Development, BeiGene USA, Inc., San Mateo/US
  • 12 Start Madrid - Ciocc, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, 28050 - Madrid/ES
More

Resources

Login to access the resources on OncologyPRO.

Abstract 535MO

Background

Preclinical studies have shown potential synergism from blocking both programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1). BGB-A333 is an investigational humanized monoclonal antibody against PD-L1 that has antitumor activity in xenograft models. Tislelizumab, a clinical-stage anti-PD-1 antibody, showed clinical activity in patients (pts) with advanced solid tumors. We report results from the expansion cohort (phase IIB) of an open-label phase I/II study (NCT03379259) of BGB-A333 plus tislelizumab in pts with previously treated advanced urothelial carcinoma (UC).

Methods

Patients received BGB-A333 1350 mg IV Q3W + tislelizumab 200 mg IV Q3W. Eligible pts had locally advanced or metastatic UC without prior PD-(L)1 therapy, could not tolerate or progressed during/after treatment with platinum-based chemotherapy, and had an ECOG performance status of ≤1. The primary endpoint was investigator-assessed objective response rate (ORR) per RECIST v1.1. Key secondary endpoints included duration of response (DoR) per RECIST v1.1, progression-free survival (PFS) estimated with Kaplan-Meier analysis, and the safety/tolerability profile evaluated by monitoring adverse events (AEs).

Results

As of 10 March 2020, 12 pts (median age, 69.5 yr; 92% male) with UC were enrolled; median study follow-up, 8.3 mo. Most pts (n=10, 83%) had 1 prior systemic therapy. Median duration of treatment for both BGB-A333 and tislelizumab was 5.5 mo (range: 1.2, 9.9). Confirmed ORR was 42% (95% CI: 15.2, 72.3); 3 pts had complete responses, 2 had partial responses, 4 had stable disease (SD; 2 had SD >6 mo), 2 had progressive disease, and 1 was not evaluable (due to missing postbaseline assessment). Median DoR was not reached; median PFS was 6.1 mo (95% CI: 1.9, not estimable). Across the entire study (n=39), treatment-related AEs (TRAEs) occurred in 19 pts. Of the 24 pts receiving combination treatment, four pts (including one with UC) had grade ≥3 TRAEs. One pt with UC had an immune-related AE (myositis); no pts with UC had a fatal TRAE.

Conclusions

BGB-A333 in combination with tislelizumab was well tolerated and demonstrated antitumor activity in pts with advanced UC.

Clinical trial identification

NCT03379259.

Editorial acknowledgement

Writing and editorial assistance was provided by Stephan Lindsey, PhD, and Elizabeth Hermans, PhD (OPEN Health Medical Communications, Chicago. IL), and funded by the study sponsor.

Legal entity responsible for the study

BeiGene, Ltd.

Funding

BeiGene, Ltd.

Disclosure

J. Martin Liberal: Speaker Bureau/Expert testimony, lecture fees: Astellas; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses, Lecture fees, advisory fees, travel grant: BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses, Lecture fees, advisory fees, travel grant: Merck Sharp & Dohme (MSD); Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses, Lecture fees, advisory fees, travel grant: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses, Lecture fees, advisory fees, travel grant: Pierre Fabre; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses, Lecture fees, travel grant: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses, Lecture fees, advisory fees, travel grant: Roche; Travel/Accommodation/Expenses, travel grant: Ipsen. P.C. Fong: Honoraria (self): AstraZeneca, Merck Sharp & Dohme; Advisory/Consultancy: Merck Sharp & Dohme; Speaker Bureau/Expert testimony: Janssen; Travel/Accommodation/Expenses: Pfizer. V. Moreno: Travel/Accommodation/Expenses, Personal Fees: BMS; Travel/Accommodation/Expenses, Personal Fees: Bayer; Travel/Accommodation/Expenses, Personal Fees: Pieris. J. Desai: Advisory/Consultancy: Amgen; Advisory/Consultancy: BeiGene; Advisory/Consultancy, Research grant/Funding (institution): Bionomics; Advisory/Consultancy: Eisai; Advisory/Consultancy: Lilly; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Roche; Research grant/Funding (institution): GlaxoSmitKline. B. Markman: Advisory/Consultancy: Novartis; Advisory/Consultancy: Amgen. M. Voskoboynik: Travel/Accommodation/Expenses, personal fees: MSD; Travel/Accommodation/Expenses, personal fees: AstraZenca. N. Budha: Shareholder/Stockholder/Stock options, Full/Part-time employment: BeiGene, Ltd. J. Wu: Shareholder/Stockholder/Stock options, Full/Part-time employment: BeiGene, Ltd. W. Shen: Full/Part-time employment: BeiGene, Ltd. M. Singh: Full/Part-time employment: BeiGene, Ltd. E. Calvo: Advisory/Consultancy, Research grant/Funding (institution): Boehringer-Ingelheim; Research grant/Funding (institution): Roche/Genentech; Research grant/Funding (institution): BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): PsiOxus; Advisory/Consultancy, Research grant/Funding (institution): Nanobiotix Janssen; Advisory/Consultancy, Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): PharmaMar; Research grant/Funding (institution): Puma, Sanofi, Lilly, Pfizer, Merck, Nektar; Advisory/Consultancy: Nanobiotix, AbbVie, AstraZenca, Guidepoint Global, GLG, PFizer, Servier, Amcure; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche/Genentech,; Honoraria (self), Full/Part-time employment: Hm Hospitals Group; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Nektar; Research grant/Funding (institution): Amcure; Research grant/Funding (institution): Amgen; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Principia Bayer; Research grant/Funding (institution): CytomX; Research grant/Funding (institution): H3; Research grant/Funding (institution): Incyte; Research grant/Funding (institution): Kura; Research grant/Funding (institution): LOXO, Macrogenics, Menarini, Merck Serono, Merus, Millenium, Rigontec, Tahio, Tesaro; Advisory/Consultancy: Janssen-Cilag; Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy: Cerulean Pharma; Advisory/Consultancy: EUSA; Advisory/Consultancy: Celgene; Full/Part-time employment, Officer/Board of Directors: START. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings